Compare USAS & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USAS | ANAB |
|---|---|---|
| Founded | 1998 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2004 | 2015 |
| Metric | USAS | ANAB |
|---|---|---|
| Price | $4.16 | $64.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 12 |
| Target Price | $6.50 | ★ $71.67 |
| AVG Volume (30 Days) | ★ 3.6M | 646.4K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $234,603,000.00 |
| Revenue This Year | $174.68 | N/A |
| Revenue Next Year | $53.17 | $52.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $0.87 | $17.11 |
| 52 Week High | $10.50 | $73.30 |
| Indicator | USAS | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 36.60 | 51.06 |
| Support Level | $3.53 | $60.94 |
| Resistance Level | $4.37 | $70.06 |
| Average True Range (ATR) | 0.29 | 4.35 |
| MACD | -0.04 | 0.29 |
| Stochastic Oscillator | 15.66 | 37.60 |
Americas Gold And Silver Corp is a mining company engaged in the acquisition, exploration, development, and production of precious metals mineral properties in Mexico and the United States. The company's primary operating assets, which are also its reporting segments, are the Cosala operations, the Galena Complex, and Relief Canyon. It also holds interests in the San Felipe Development Project located in Sonora, Mexico. The Cosala operations segment, which derives maximum revenue, operates in Mexico, while the Galena Complex and Relief Canyon segments operate in the United States.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).